ICON plc (NASDAQ: ICLR), a global provider
of drug development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that
all resolutions at the Annual General Meeting of the Company (AGM)
held on July 24, 2015 (which resolutions had all been recommended
by the Board) were all duly passed by shareholders. These
resolutions were set out in the Notice of the AGM sent to
shareholders dated June 12, 2015 and are available on the
ICON plc website.
The resolutions were all passed and the final results of proxy
voting were:
RESOLUTION NUMBER RESOLUTION
TOTAL NUMBER OF VOTES
VOTE FOR VOTE AGAINST
VOTE WITHHELD
1.1
To re-elect Mr. Ciaran
Murray
50,029,986 49,567,723
247,632 214,631
1.2
To re-elect Dr. Ronan
Lambe
50,029,986 47,186,311
2,628,744 214,931
1.3
To re-elect Mr. Declan
McKeon
50,029,986 48,645,702
1,169,472 214,812
2
To receive accounts
and reports
50,029,986 49,641,405
3,516 385,065
3
To authorise the
fixing of the auditors’
remuneration
50,029,986 45,084,310
4,796,085 149,591
4**
To authorise the
Company to allot
shares
50,029,986 48,491,411
1,379,197 159,378
5**
To disapply
pre-emption rights
50,029,986 49,701,576
154,711 173,699
6**
To authorise the
Company to make
market purchases of
shares
50,029,986 49,004,400
149,069 876,517
7**
To authorise the price
range at which the
Company can
reissue shares it
holds as treasury
shares
50,029,986 49,842,211
27,891 159,884
** Special Resolution. All resolutions are ordinary resolutions
unless otherwise stated.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 81 locations in 37 countries and has approximately
11,300 employees. Further information is available at
www.iconplc.com.
ICON/ICLR-F
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150727005485/en/
All at ICONInvestor Relations, 1-888-381-7923orBrendan Brennan,
+ 353 –1-291-2000Chief Financial OfficerorSimon Holmes, + 353
–1-291-2000EVP Investor Relations and Corporate Development
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024